Albany Molecular Research Inc. Announces Licensing Deal With Bristol-Myers Squibb Company
ALBANY, N.Y.--(BUSINESS WIRE)--Oct. 24, 2005--Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced a licensing agreement with Bristol-Myers Squibb (NYSE: BMY) for its broad program of compounds that encompass biogenic amine reuptake inhibitors in development for the treatment of depression and other central nervous system disorders.